SYNLOGIC, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
PO BOX 30, WINCHESTER, MA, 01890
Mailing Address
PO BOX 30, WINCHESTER, MA, 01890
Phone
617-659-2802
Fiscal Year End
1231
EIN
261824804
Financial Overview
FY2025 FY
-
Revenue
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 12, 2026 | View on SEC |
| 8-K/A Current report amendment | January 29, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 23, 2026 | View on SEC |
| 8-K Current report of material events | January 20, 2026 | View on SEC |
| 8-K Current report of material events | December 16, 2025 | View on SEC |
| 8-K Current report of material events | November 26, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 13, 2025 | View on SEC |
| DEF 14A Definitive proxy statement | November 12, 2025 | View on SEC |
| 4 Insider stock transaction report | October 31, 2025 | View on SEC |
Annual Reports
10-K
March 12, 2026
- SYNLOGIC, INC. has strategically reoriented from a biopharmaceutical developer to a 'public shell' company, focusing on identifying a value-enhancing strategic transaction.
- The company's public company status is now its primary asset, offering a potential vehicle for a merger, sale, or acquisition of new businesses.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.